Bonus Biogroup

Bonus Biogroup FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Bonus Biogroup (BONS.TA) as of Oct 17, 2026 is 61.02 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 78.04 % — a change of -21.81% (lower).

FCF Conversion

61.02 %

YoY

-21.81%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Bonus Biogroup is 2025 61.02 % . FCF Conversion Rate (FCF/EBITDA) of Bonus Biogroup was 2024 78.04 % . It decreases by -21.81% lower compared to the previous year.

The Bonus Biogroup FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
73.49 ILS
Jan 1, 2019
59.80 ILS
Jan 1, 2020
72.66 ILS
Jan 1, 2021
50.68 ILS
Jan 1, 2022
90.96 ILS
Jan 1, 2023
95.42 ILS
Jan 1, 2024
78.04 ILS
Jan 1, 2025
61.02 ILS
The Bonus Biogroup FCF Conversion history
YEARFCF ConversionYoY
61.02 %-21.81%
78.04 %-18.21%
95.42 %+4.90%
90.96 %+79.49%
50.68 %-30.25%
72.66 %+21.50%
59.80 %-18.62%
73.49 %+22.75%
59.87 %-2.13%
61.17 %+0.94%
60.61 %-19.55%
75.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bonus Biogroup Stock analysis

What does Bonus Biogroup do? The Bonus Biogroup Ltd is a biotechnology company based in Israel that specializes in the development and marketing of innovative medical products and therapies based on human bone marrow stem cells. The company was founded in 2008 by a group of scientists, doctors, and entrepreneurs who came together to explore and develop new approaches in regenerative medicine. The business model of Bonus Biogroup is based on utilizing the benefits of stem cells for tissue and organ regeneration. Mesenchymal stem cells (MSC), derived from bone marrow, play an important role in this process. These stem cells have the ability to differentiate into various cell types and have anti-inflammatory properties. Bonus Biogroup aims to utilize MSC technology for the development of innovative medical products and therapies to help patients with serious diseases. The company is divided into several business areas, each offering its own products and services. A key area is the development of implants and other medical devices coated with bone marrow stem cells. These products are intended to promote tissue regeneration in the body, particularly in the treatment of bone and cartilage defects and joint diseases. An example is the BioGrip implant, used in patients with osteoporosis to prevent or reduce bone fractures. Another business area of Bonus Biogroup is the production and marketing of cell therapies. In this process, mesenchymal stem cells are obtained from the patient's bone marrow and processed in a special procedure. The stem cells are then directly injected into the affected area to promote tissue regeneration. These cell therapies are used in patients with rheumatism, arthritis, joint pain, or spinal problems. In addition to research and development of new products and therapies, Bonus Biogroup also operates a large stem cell bank. This bank collects and stores human bone marrow from donors for later use in the production of implants and cell therapies. The stem cell bank is a crucial part of the business model, as it ensures a consistent and high-quality supply of mesenchymal stem cells. In summary, Bonus Biogroup is an innovative biotechnology company specializing in the use of human bone marrow stem cells. The business model is based on the development and marketing of implants, cell therapies, and other medical devices to promote tissue regeneration in the body. The company also operates a large stem cell bank to ensure a consistent supply of high-quality mesenchymal stem cells. The company has the potential to become a significant player in regenerative medicine, making a valuable contribution to improving the health and quality of life of patients. Bonus Biogroup is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bonus Biogroup stock

FCF Conversion Rate (FCF/EBITDA) of Bonus Biogroup is 61.02 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Bonus Biogroup changed from 78.04 % to 61.02 %, representing a -21.81% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Bonus Biogroup since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Bonus Biogroup with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bonus Biogroup

All Key Metrics — Bonus Biogroup